Central Lab for AIDS Vaccine Clinical Trials

Bolognesi, Dan P.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Research and Development Contracts (N01)
• Project #: N01AI015106-007
• Application #: 2295053
• Project Start: 1991-03-12
• Project End: 1996-03-11
• Budget Start: 1993-09-10
• Budget End: 1994-09-15
• Fiscal Year: 1993

Institution

• Name: Duke University
• Type: Organized Research Units
• DUNS #: 071723621
• City: Durham
• State: NC
• Country: United States
• Zip Code: 27705

Publications

Gorse, G J; Corey, L; Patel, G B et al. (1999) HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 15:115-32

Gorse, G J; McElrath, M J; Matthews, T J et al. (1998) Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Vaccine 16:493-506

Gorse, G J; Patel, G B; Newman, F K et al. (1996) Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. Clin Diagn Lab Immunol 3:378-86

Keefer, M C; Graham, B S; McElrath, M J et al. (1996) Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 12:683-93